{"id":34569,"date":"2025-01-31T09:48:13","date_gmt":"2025-01-31T15:48:13","guid":{"rendered":"https:\/\/brakkeconsulting.com\/?p=34569"},"modified":"2025-01-31T09:48:13","modified_gmt":"2025-01-31T15:48:13","slug":"brakke-viewpoint-january-31-2025","status":"publish","type":"post","link":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-january-31-2025\/","title":{"rendered":"Mirante de Brakke 31 de janeiro de 2025"},"content":{"rendered":"<p>Foi \u00f3timo ver muitos dos nossos assinantes do News &amp; Notes na confer\u00eancia VMX em Orlando esta semana e somos muito gratos \u00e0queles que compareceram \u00e0 Vis\u00e3o Geral da Ind\u00fastria de Sa\u00fade Animal de 2025 na tarde de segunda-feira. Esta foi a sess\u00e3o mais bem frequentada que j\u00e1 tivemos, ent\u00e3o, obrigado a todos voc\u00eas pelo apoio.<\/p>\n<p>Enquanto eu caminhava pelo sal\u00e3o de exposi\u00e7\u00e3o e conversava com os expositores, todos pareciam estar positivos sobre 2025, especialmente aqueles com novos produtos para lan\u00e7ar. O parasiticida combinado da Elanco, Credlio Quattro, foi lan\u00e7ado e a empresa estava recebendo pedidos, junto com o Zenrelia recentemente aprovado para dermatite at\u00f3pica. Houve algum burburinho em torno do parasiticida injet\u00e1vel Bravecto da Merck e poss\u00edvel produto dermatol\u00f3gico no final do ano.<\/p>\n<p>Outro lan\u00e7amento not\u00e1vel foi o novo teste de detec\u00e7\u00e3o precoce de linfoma da IDEXX \u2013 IDEXX Cancer Dx \u2013 not\u00e1vel por sua acessibilidade e capacidade de expans\u00e3o para outros tipos de c\u00e2ncer. Houve alguma conversa sobre o Librela da Zoetis para dor de OA canina, mas minha sensa\u00e7\u00e3o \u00e9 que os veterin\u00e1rios est\u00e3o simplesmente aprendendo a us\u00e1-lo \u2013 meu labrador retriever atl\u00e9tico de 10 anos est\u00e1 indo muito bem ap\u00f3s sua terceira inje\u00e7\u00e3o.<\/p>\n<p>Realizaremos nossa Industry Overview na WVC em Las Vegas no dia 3 de mar\u00e7o, ent\u00e3o se voc\u00ea perdeu a de Orlando, ainda tem uma chance de comparecer. Espero ver voc\u00ea l\u00e1.<\/p>\n<p><em>Bob Jones<\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Foi \u00f3timo ver muitos dos nossos assinantes do News &amp; Notes na confer\u00eancia VMX em Orlando esta semana e somos muito gratos \u00e0queles que compareceram \u00e0 Vis\u00e3o Geral da Ind\u00fastria de Sa\u00fade Animal de 2025 na tarde de segunda-feira. Esta foi a sess\u00e3o mais concorrida que j\u00e1 tivemos, ent\u00e3o obrigado a todos pelo apoio. Enquanto eu caminhava pelo sal\u00e3o de exposi\u00e7\u00e3o e conversava com os expositores, todos pareciam estar otimistas em rela\u00e7\u00e3o a 2025, especialmente aqueles com novos produtos para lan\u00e7ar. O parasiticida combinado da Elanco, Credlio Quattro, foi lan\u00e7ado e a empresa estava recebendo encomendas, juntamente com o Zenrelia, recentemente aprovado para dermatite at\u00f3pica. Houve algum burburinho em torno do parasiticida injet\u00e1vel Bravecto da Merck e de um poss\u00edvel produto dermatol\u00f3gico no final do ano. Outro lan\u00e7amento not\u00e1vel foi o novo teste de detec\u00e7\u00e3o precoce de linfoma da IDEXX \u2013 IDEXX Cancer Dx \u2013 not\u00e1vel por sua acessibilidade e capacidade de expans\u00e3o para outros tipos de c\u00e2ncer. Houve alguma conversa sobre o Librela da Zoetis para a dor da osteoartrite canina, mas minha impress\u00e3o \u00e9 que os veterin\u00e1rios est\u00e3o apenas aprendendo a us\u00e1-lo \u2013 meu labrador retriever de 10 anos est\u00e1 se saindo muito bem ap\u00f3s a terceira inje\u00e7\u00e3o. Realizaremos nossa Vis\u00e3o Geral do Setor na WVC em Las Vegas no dia 3 de mar\u00e7o, ent\u00e3o, se voc\u00ea perdeu a de Orlando, ainda tem a chance de comparecer. Espero v\u00ea-lo l\u00e1. Bob Jones<\/p>","protected":false},"author":19,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[43],"tags":[],"class_list":["post-34569","post","type-post","status-publish","format-standard","hentry","category-viewpoints"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>News from Brakke Consulting<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-january-31-2025\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from Brakke Consulting\" \/>\n<meta property=\"og:description\" content=\"It was great to see many of our News &amp; Notes subscribers at the VMX conference in Orlando this week and we are very grateful to those that attended the 2025 Animal Health Industry Overview on Monday afternoon.\u00a0 This was the best attended session we have ever had, so thanks to all of you for your support. As I walked the exhibition hall and talked to the exhibitors, everyone seemed to be positive about 2025, especially those with new products to launch.\u00a0 Elanco\u2019s combination parasiticide, Credlio Quattro was launched and the company was taking orders, along with recently approved Zenrelia for atopic dermatitis.\u00a0 There was some buzz around Merck\u2019s injectable Bravecto parasiticide and possible dermatology product later in the year. Another notable launch was IDEXX\u2019s new lymphoma early detection test \u2013 IDEXX Cancer Dx &#8211; notable for its affordability and ability to expand on to other cancers.\u00a0 There was some talk about Zoetis\u2019s Librela for canine OA pain, but my sense is that veterinarians are simply learning how to use it \u2013 my 10-year-old athletic Labrador retriever is doing fantastic after his third injection. We will hold our Industry Overview at WVC in Las Vegas on March 3rd, so if you missed the one in Orlando, you still have a chance to attend.\u00a0 Hope to see you there. Bob Jones\" \/>\n<meta property=\"og:url\" content=\"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-january-31-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Brakke Consulting Website\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-31T15:48:13+00:00\" \/>\n<meta name=\"author\" content=\"Amanda McDavid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Amanda McDavid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/\"},\"author\":{\"name\":\"Amanda McDavid\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"headline\":\"Brakke Viewpoint January 31, 2025\",\"datePublished\":\"2025-01-31T15:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/\"},\"wordCount\":223,\"articleSection\":[\"Viewpoints\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/\",\"url\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/\",\"name\":\"News from Brakke Consulting\",\"isPartOf\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#website\"},\"datePublished\":\"2025-01-31T15:48:13+00:00\",\"author\":{\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\"},\"breadcrumb\":{\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/brakkeconsulting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brakke Viewpoint January 31, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/brakkeconsulting.com\/#website\",\"url\":\"https:\/\/brakkeconsulting.com\/\",\"name\":\"Brakke Consulting Website\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/brakkeconsulting.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615\",\"name\":\"Amanda McDavid\",\"url\":\"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Not\u00edcias da Brakke Consulting","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-january-31-2025\/","og_locale":"pt_PT","og_type":"article","og_title":"News from Brakke Consulting","og_description":"It was great to see many of our News &amp; Notes subscribers at the VMX conference in Orlando this week and we are very grateful to those that attended the 2025 Animal Health Industry Overview on Monday afternoon.\u00a0 This was the best attended session we have ever had, so thanks to all of you for your support. As I walked the exhibition hall and talked to the exhibitors, everyone seemed to be positive about 2025, especially those with new products to launch.\u00a0 Elanco\u2019s combination parasiticide, Credlio Quattro was launched and the company was taking orders, along with recently approved Zenrelia for atopic dermatitis.\u00a0 There was some buzz around Merck\u2019s injectable Bravecto parasiticide and possible dermatology product later in the year. Another notable launch was IDEXX\u2019s new lymphoma early detection test \u2013 IDEXX Cancer Dx &#8211; notable for its affordability and ability to expand on to other cancers.\u00a0 There was some talk about Zoetis\u2019s Librela for canine OA pain, but my sense is that veterinarians are simply learning how to use it \u2013 my 10-year-old athletic Labrador retriever is doing fantastic after his third injection. We will hold our Industry Overview at WVC in Las Vegas on March 3rd, so if you missed the one in Orlando, you still have a chance to attend.\u00a0 Hope to see you there. Bob Jones","og_url":"https:\/\/brakkeconsulting.com\/pt\/brakke-viewpoint-january-31-2025\/","og_site_name":"Brakke Consulting Website","article_published_time":"2025-01-31T15:48:13+00:00","author":"Amanda McDavid","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Amanda McDavid","Tempo estimado de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/#article","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/"},"author":{"name":"Amanda McDavid","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"headline":"Brakke Viewpoint January 31, 2025","datePublished":"2025-01-31T15:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/"},"wordCount":223,"articleSection":["Viewpoints"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/","url":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/","name":"Not\u00edcias da Brakke Consulting","isPartOf":{"@id":"https:\/\/brakkeconsulting.com\/#website"},"datePublished":"2025-01-31T15:48:13+00:00","author":{"@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615"},"breadcrumb":{"@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/brakkeconsulting.com\/ja\/brakke-viewpoint-january-31-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/brakkeconsulting.com\/"},{"@type":"ListItem","position":2,"name":"Brakke Viewpoint January 31, 2025"}]},{"@type":"WebSite","@id":"https:\/\/brakkeconsulting.com\/#website","url":"https:\/\/brakkeconsulting.com\/","name":"Site da Brakke Consulting","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/brakkeconsulting.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Person","@id":"https:\/\/brakkeconsulting.com\/#\/schema\/person\/cbd3330707aa1f20925a2f9d78722615","name":"Amanda McDavid","url":"https:\/\/brakkeconsulting.com\/pt\/author\/amanda\/"}]}},"_links":{"self":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/34569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/comments?post=34569"}],"version-history":[{"count":1,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/34569\/revisions"}],"predecessor-version":[{"id":34571,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/posts\/34569\/revisions\/34571"}],"wp:attachment":[{"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/media?parent=34569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/categories?post=34569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/brakkeconsulting.com\/pt\/wp-json\/wp\/v2\/tags?post=34569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}